Tenaya Therapeutics Files 8-K with Material Agreement
Ticker: TNYA · Form: 8-K · Filed: Mar 4, 2025 · CIK: 1858848
| Field | Detail |
|---|---|
| Company | Tenaya Therapeutics, Inc. (TNYA) |
| Form Type | 8-K |
| Filed Date | Mar 4, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement, 8-k, disclosure
TL;DR
Tenaya Therapeutics signed a material definitive agreement, filing an 8-K on March 4, 2025.
AI Summary
On March 3, 2025, Tenaya Therapeutics, Inc. entered into a material definitive agreement. The company also made a Regulation FD disclosure and reported other events, including financial statements and exhibits. The filing was made on March 4, 2025.
Why It Matters
This 8-K filing indicates a significant new agreement for Tenaya Therapeutics, which could impact its business operations and future financial performance.
Risk Assessment
Risk Level: medium — Material definitive agreements can introduce new risks or opportunities that are not yet fully understood by the market.
Key Players & Entities
- Tenaya Therapeutics, Inc. (company) — Registrant
- March 3, 2025 (date) — Date of earliest event reported
- March 4, 2025 (date) — Filing date
- 171 Oyster Point Boulevard, Suite 500 (address) — Principal executive offices
- South San Francisco, CA 94080 (address) — Principal executive offices
FAQ
What is the nature of the material definitive agreement entered into by Tenaya Therapeutics?
The filing does not specify the details of the material definitive agreement, only that one was entered into on March 3, 2025.
What other items are included in this 8-K filing?
The filing includes a Regulation FD disclosure, other events, and financial statements and exhibits.
When was this 8-K form filed with the SEC?
The 8-K form was filed on March 4, 2025.
What is Tenaya Therapeutics' principal executive office address?
Tenaya Therapeutics' principal executive offices are located at 171 Oyster Point Boulevard, Suite 500, South San Francisco, CA 94080.
What is Tenaya Therapeutics' state of incorporation and fiscal year end?
Tenaya Therapeutics is incorporated in Delaware and its fiscal year ends on December 31.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on March 4, 2025 regarding Tenaya Therapeutics, Inc. (TNYA).